Baseline characteristics and differences in short- and long-term response to rhGH between GHD adults with craniopharyngioma and nonfunctioning pituitary adenoma

E. Profka; C. Giavoli; S. Bergamaschi; E. Ferrante; E. Malchiodi; E. Sala; E. Verrua; A. Spada; P. Beck-Peccoz

P1002

Prev Next

Section Contents Cite

Endocrine Abstracts (2012) 29 P1002

ICEECE2012 Poster Presentations Growth hormone IGF axis - basic (23 abstracts)

Baseline characteristics and differences in short- and long-term response to rhGH between GHD adults with craniopharyngioma and nonfunctioning pituitary adenoma

E. Profka ^1, , C. Giavoli ^1, , S. Bergamaschi ^1, , E. Ferrante ^1, , E. Malchiodi ^1, , E. Sala ^1, , E. Verrua ^1, , A. Spada ^1, & P. Beck-Peccoz ^1,

Views

Author affiliations

¹Milan Italy; ²Unit of Endocrinology and Diabetology, Milan, Italy.

Patients with craniopharyngioma (CP) are more often operated by transcranial route than patients with nonfunctioning pituitary adenoma (NFPA), have higher prevalence of pituitary deficiencies, are more obese and dyslipidemic and have a higher mortality rate. A previous study in a large group of GHD subjects, showed that the effects of 2-year rhGH replacement are similar in patients operated for CP and in patients operated for NFPA, except for less reduction in fat mass in CP patients. Aim of the study was to compare both short- (12 months) and long-term (mean follow-up 8 years, range 3–14 years) effects of rhGH in 26 GHD adults patients, 12 operated for CP and 14 for NFPA. Serum IGF-I, lipid profile, glucose metabolism, insulin resistance (HOMA-IR), anthropometric parameters and body composition (BF%) were evaluated. At baseline, no difference between the two groups was observed. After 12 months, SDS IGF-I normalized and BF% significantly decreased in both groups. Concerning long-term effects, increase in IGF-I levels was maintained, while persistent decrease in BF% was observed only in NFPA group. Comparing the data between groups at each follow-up, CP group had a lower ΔBF% than NFPA group (−3.4±2 vs −10.1±10, at short-term, P<0.04 and −0.7±11 vs −11±13.7, at long-term, P<0.05, respectively), as well as higher serum insulin levels (19±15 vs 9.4±6.5, P<0.04 and 16.2±10.4 vs 9±4 uIU/mL, P< 0.03 respectively) and higher HOMA-IR (4.1±3.2 vs 2±1.3, P<0.04 and 4.4±4.5 vs 1.9±0.9, P<0.05, respectively). In conclusion, we confirm in the long term study the minor BF% reduction in CP versus NFPA patients. Moreover, patients with CP were more prone to develop insulin resistance than NFPA patients.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.